- Toripalimab plus chemotherapy provided superior progression free survival, overall survival, overall response rate and duration of response compared to…
COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company” and, together with…
- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors - - Butyrophilin…
LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of…
Preclinical data demonstrated POC with robust in vitro and in vivo anti-tumor activityUCART20x22 allogeneic dual CAR T has been designed…
Three poster presentations highlight the unmet need for targeted therapies in BRAF and/or NRAS-altered cancers, including non-small cell lung cancer…
YIV-906 is a botanical cancer drug Scutellaria baicalensis is one of four components of the cancer drug YIV-906 and found…
Updated Data as of December 1, 2021 from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic MelanomaThree-year…
This release replaces one sent out last week that had the wrong headline.There Are Reasons Neglected Tropical Diseases Shouldn't Stay…
NEW YORK--(BUSINESS WIRE)--#Class--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Stryker…